HCPLive Network

Phase 3 Trial of Experimental Gout Drug Lesinurad to Begin

Phase 3 Trial of Experimental Gout Drug Lesinurad to BeginArdea Biosciences announced on Monday that it would soon begin the first of four planned Phase 3 clinical trials of its experimental gout drug lesinurad. The trial is expected to include around 2,000 gout patients at study sites around the world.
 
Lesinurad is an oral inhibitor of the URAT1 transporter in the kidney that regulates uric acid excretion. According to a press release from Ardea Biosciences, around 90% of gout patients are thought to excrete too little uric acid, and studies have found that defective renal transporters, which promote excretion of uric acid under normal circumstances, are genetically linked to gout.
 
Since currently available gout drugs such as the xanthine oxidase inhibitors allopurinol and febuxostat have a mechanism of action different from URAT1 inhibitors, the hope is that lesinurad will be able to be used in conjunction with these other drugs to help the many gout patients who are not adequately treated with existing therapies alone. In previous Phase 1 and 2 trials, lesinurad has been tested on over 700 patients as a single agent and in combination with allopurinol and febuxostat.

Further Reading
Trulicity (dulaglutide) is a once-weekly subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
There is little evidence that testosterone replacement therapy effectively treats normally declining levels of the hormone in aging American males, a US Food and Drug Administration advisory panel said Wednesday.
Reports suggest that combination therapy with the drug afamelanotide and narrowband ultraviolet-B ray (NB UVB) phototherapy is safe and effective for restoring skin pigmentation in patients with vitiligo, a skin disease resulting from dead melanin-producing cells with no current cure.
The rate of major adverse cardiovascular events is higher in patients with diabetes mellitus and multivessel coronary artery disease treated with insulin versus those not treated with insulin, according to a study published in the Sept. 23 issue of the Journal of the American College of Cardiology.
Stendra (avanafil) is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.
Scientists have uncovered a key factor to explain why antibiotic-resistant bacteria can thrive in a hospital setting. These findings have published in the Sept. 17 issue of Science Translational Medicine.
Use of electronic medical record systems is associated with considerable loss of free time per clinic day, according to a research letter published online Sept. 8 in JAMA Internal Medicine.
More Reading